Trials / Unknown
UnknownNCT04971447
Extracellular Vesicles and Endothelial Function in Transgender Subjects
Effects of Plasma Extracellular Vesicles on Endothelial Function in Transgender Subjects
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
Cardiovascular diseases are the leading cause of mortality. In women, the prevalence of cardiovascular diseases is lower and the presentation of coronary events often atypical. The lack of evidence is related in part to the methodology of studies not considering sex as an essential biological variable. Hormonal treatment is prescribed in transgender subjects to promote the development of sexual characteristics of the desired sex. Early cardiovascular effects of hormonal treatment have been reported in transgender men, while long-term mortality is higher in transgender women. The aim of this project is to study the effects of gender affirming hormonal treatment on arterial stiffness in young transgender subjects followed at the University Hospital of Nancy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gender affirming hormonal treatment in transgender men | testosterone enanthate |
| DRUG | gender affirming hormonal treatment in transgender women | GnRH agonists + estrogen |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-09-01
- Completion
- 2024-01-01
- First posted
- 2021-07-21
- Last updated
- 2022-07-25
Source: ClinicalTrials.gov record NCT04971447. Inclusion in this directory is not an endorsement.